BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SenzaGen - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SenzaGen
X-ORIGINAL-URL:https://senzagen.com
X-WR-CALDESC:Events for SenzaGen
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20270314T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20271107T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250404
DTEND;VALUE=DATE:20250405
DTSTAMP:20250317T145119Z
CREATED:20250317T134428Z
LAST-MODIFIED:20250317T145119Z
UID:34368-1743724800-1743811199@senzagen.com
SUMMARY:2025 SFT annual meeting
DESCRIPTION:Meet us at Swedish Society of Toxicology (SFT)’s annual meeting in Stockholm! This year the theme is “Breaking boundaries: novel methods and approaches advancing toxicology”. \nDate: April 4\, 2025 \nVenue: Samuelssonssalen\, Karolinska Institutet\, Tomtebodavägen 6\, Solna \nSenzaGen’s presentation: Advancing skin sensitization testing with GARD®: Enhancing human relevance and overcoming regulatory challenges \nSpeaker: Tim Lindberg\, PhD\, In vitro Toxicology Expert\, SenzaGen
URL:https://senzagen.com/event/2025sft/
LOCATION:Stockholm\, Sweden
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/03/KI_Samuelssonssalen-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250404
DTEND;VALUE=DATE:20250411
DTSTAMP:20250317T150648Z
CREATED:20250317T145617Z
LAST-MODIFIED:20250317T150648Z
UID:34382-1743724800-1744329599@senzagen.com
SUMMARY:In-cosmetics Global 2025
DESCRIPTION:Meet us at In-cosmetics global in Amsterdam!  \nDate: April 8-10\, 2025
URL:https://senzagen.com/event/2025in-cosmetics-global/
LOCATION:Amsterdam\, Netherlands
CATEGORIES:Conference
ATTACH;FMTTYPE=image/webp:https://senzagen.com/wp-content/uploads/2025/03/INCOS-Global_370x125_Atlas-logo.png.webp
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250831
DTEND;VALUE=DATE:20250905
DTSTAMP:20250828T194641Z
CREATED:20250303T121220Z
LAST-MODIFIED:20250828T194641Z
UID:34240-1756598400-1757030399@senzagen.com
SUMMARY:WC13
DESCRIPTION:13th World Congress on Alternatives and Animal Use in the Life Sciences\n📍 Rio de Janeiro\, Brazil | 🗓 Aug 31-Sep 4\nAt this year’s conference SenzaGen and Unilever co-chair a scientific symposium\, where Dr Andy Forreryd will present how GARD® can be applied to derive a Point-of-Departure (PoD) for quantitative skin sensitization assessment. \n \nSession #79\nUsing NAMs to derive PoDs for NGRA of skin sensitizers: Towards regulatory implementation\nTime: 9:30-11:00 | Tuesday\, September 2\nVenue: Plenary Room\nTogether with speakers from Unilever\, Research Institute for Fragrance Materials (RIFM)\, and Inotiv\, this joint symposium will cover methodological innovations in New Approach Methodologies (NAMs)\, industry case studies on deriving Points of Departure (PoDs) for fragrances\, and the challenges and opportunities for regulatory acceptance. \n \n💻 Incorporating expert knowledge in the Skin Allergy Risk Assessment (SARA) Model: an integrated approach to testing and assessment (IATA) demonstrated in case studies.\nRenato Ivan de Ávila\, PhD @Unilever \n💻 The GARD®skin Dose-Response model to derive a PoD for quantitative skin sensitization assessment.\nAndy Forreryd\, PhD @SenzaGen \n💻 Predicting PoD and potency categories using New Approach Methods: Practical experience from the fragrance industry.\nIsabella Schember\, PhD @Research Institute for Fragrance Materials (RIFM) \n💻 Integrating NAMs for quantitative skin sensitization potency assessment into regulatory frameworks: experience from the work in OECD TG 497\nEmily Reinke\, PhD\, D.A.B.T @Inotiv \nPoster #167\nGARD®skin for Medical Devices: Pre-validation results for implementation in ISO 10993-10\nThe pre-validation study of GARD®skin Medical Device confirms the method is functional\, reproducible and sufficiently accurate to proceed to the validation study phase\, as defined by the ISO TS11796.
URL:https://senzagen.com/event/wc13/
LOCATION:Rio de Janeiro\, Brazil
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/WC13-Logo-white-background.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250914
DTEND;VALUE=DATE:20250918
DTSTAMP:20250909T111839Z
CREATED:20250317T151319Z
LAST-MODIFIED:20250909T111839Z
UID:34391-1757808000-1758153599@senzagen.com
SUMMARY:Eurotox 2025
DESCRIPTION:Eurotox 2025\n Athens\, Greece |  Sep 14-17\nBooth #A24\nAdvancing NAMs for Skin Sensitization Testing\nCome meet us at this year’s Eurotox and take part in our scientific activities\, featuring an industry-hosted session\, poster presentations\, and the latest insights on GARD®. Discover how the method provides high performance\, broad applicability\, and quantitative potency information for skin sensitization testing. \nWant to connect with our scientific team while you’re there? \n \nIndustry-Hosted Session\nRegulatory update: GARD®skin in OECD TG 497\nTime: 12:00-13:00 | Tuesday\, September 16\nVenue: N. Skalkotas Hall\n \nJoin us for an interactive scientific session featuring regulatory updates\, case studies\, and a live Q&A. Key highlights: \n\nRegulatory update: GARD®skin included in OECD TG 497.\nCase studies: UVCBs\, Natural Extracts\, Formulations\, Hydrophobic Substances\, and more.\nScientific collaborations: dōTERRA\, BIC\, and Urgo.\n\nLearn how GARD®skin fits into TG 497 and what this means in practice for your regulatory testing strategy. \nPosters\nSpotlight on Essential oils\, Safe dose levels\, Hypoallergenic claims and more\n🎫 P32-09 #644 | Joint poster with DōTERRA\nComparative analysis of skin sensitization thresholds for essential oils: human\, murine\, and GARDskin Dose-Response \n🎫 P32-12 #731 | Joint poster with BIC Skin Creative\nIn vitro skin sensitization potency assessment using GARDskin Dose-Response: a case study on natural extracts-based skin-binding dyes and dye precursors \n🎫 P32-16 #923 | Joint poster with Urgo\nSupporting industry decision-making and hypoallergenicity claims using an experimental setup combining GARDskin Medical Device and Dose-Response protocols \n🎫 P23-04 #314 | ToxHub poster\nDeriving gender-sensitive Occupational Exposure Limits: Case studies on benperidol and dimethylacetamide \nMore at our booth\nExpert guidance for your regulatory challenges\nMeet ToxHub\, our consultancy unit specializing in toxicological risk assessment and regulatory strategy consulting\, with expertise across medical devices\, pharmaceuticals\, cosmetics and chemicals. \nDiscover how ToxHub can support your needs
URL:https://senzagen.com/event/eurotox-2025/
LOCATION:Athens\, Greece
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/03/2025-eurotox-banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20250929T100000
DTEND;TZID=Europe/Stockholm:20250929T190000
DTSTAMP:20250828T194205Z
CREATED:20250828T131114Z
LAST-MODIFIED:20250828T194205Z
UID:35415-1759140000-1759172400@senzagen.com
SUMMARY:RIFM INFOX 2025
DESCRIPTION:RIFM 2025 Information Exchange (INFOX®) Paris\nFrance Advancing Fragrance Safety Through Innovation\, Science\, and Collaboration\nDate: September 29\, 2025\nLocation: Le Méridien Etoile\, 81 Bd Gouvion-Saint-Cyr\, 75017 Paris\, France\nCome meet SenzaGen’ skin sensitization experts Dr Andy Forreryd and Dr Tim Lindberg at this year’s Research Institute for Fragrance Materials (RIFM) INFOX© meeting in Paris! \nThis exclusive event brings together leading scientists to present the latest advancements in fragrance safety science\, spanning human health and environmental protection. INFOX 2025 is a key forum for shaping the future of safe and sustainable fragrance use\, and we look forward to engaging in the discussions. \nWant to connect with our scientific team while you are in Paris?
URL:https://senzagen.com/event/rifm-infox-2025/
LOCATION:Paris\, France
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/08/INFOX-GENERAL-HEADER-1024x535-1-e1756387095780.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251015
DTEND;VALUE=DATE:20251019
DTSTAMP:20250828T195046Z
CREATED:20250828T135526Z
LAST-MODIFIED:20250828T195046Z
UID:35428-1760486400-1760831999@senzagen.com
SUMMARY:ICT/IUTOX 2025
DESCRIPTION:ICT 2025 / IUTOX 17th International Congress of Toxicology\n📍 Beijing\, China | 🗓 October 15–18\, 2025\nMeet us at this year’s ICT/IUTOX conference in Beijing\, where SenzaGen’s scientific team will share new insights on quantitative skin sensitization potency assessment and present results from the pre-validation study of GARD®skin Medical Device. \nWhat to connect with us while you are there? \n \nPosters\n🎫  #645 | Quantitative skin sensitization potency assessment\nAdvancing in vitro skin sensitization potency assessment using GARDskin Dose-Response \n🎫 #649 | Application for medical devices\nPre-validation results from GARDskin for Medical Devices: In vitro sensitization testing of medical device extracts for implementation in ISO 10993-10
URL:https://senzagen.com/event/ict-iutox-2025/
LOCATION:Beijing\, China
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/08/ICT-banner-e1756389255388.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251021
DTEND;VALUE=DATE:20251024
DTSTAMP:20250828T193940Z
CREATED:20250828T140923Z
LAST-MODIFIED:20250828T193940Z
UID:35446-1761004800-1761263999@senzagen.com
SUMMARY:ASCCT 2025
DESCRIPTION:ASCCT 14th Annual Meeting\n📍 Gaithersburg\, USA | 🗓 October 21–23\, 2025\nMeet us at this year’s ASCCT annual meeting in Gaithersburg\, where SenzaGen’s scientific team will share new insights on quantitative skin sensitization potency assessment and present results from the pre-validation study of GARD®skin Medical Device. \nWhat to connect with us while you are there? \n \nMore information coming soon!
URL:https://senzagen.com/event/ascct-2025/
LOCATION:Gaithersburg\, Md\, USA
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2025/08/25133-RAD-ASCCT-Annual-Meeting-Graphics_IIVS-Update-1584x396-1-e1756392285881.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20251106
DTEND;VALUE=DATE:20251108
DTSTAMP:20251028T132753Z
CREATED:20250828T142424Z
LAST-MODIFIED:20251028T132753Z
UID:35451-1762387200-1762559999@senzagen.com
SUMMARY:3rd Annual Medical Device Biocompatibility Conference
DESCRIPTION:3rd Annual Medical Device Biocompatibility Conference\n Berlin\, Germany |  Nov 6-7\nCome meet us at this year’s Medical Device Biocompatibility Conference in Berlin\, where SenzaGen’s chief scientist Henrik Johansson will present recent progress in applying New Approach Methodologies (NAMs) for skin sensitization testing within the ISO 10993 framework\, including current regulatory developments and data from GARD®skin for Medical Devices. \nOur group company ToxHub will also present\, sharing insights on regulatory strategies for substance-based medical devices in line with MDR\, while VitroScreen will attend to discuss testing approaches\, including support for mode of action and classification. \nWant to connect with our scientific team while you’re there? \n \nPresentations\n“Building Confidence in New Approach Methodologies (NAMs) for Skin Sensitization Testing of Medical Devices”\n Thursday\, 6th Nov | 13:30 – 14:00 CET\n👤 Speaker: Dr Henrik Johansson\, Chief Scientist at SenzaGen\nKey takeaways:\n\nIntroduction to in vitro biocompatibility testing: Overview of available assays and their regulatory status.\nPre-validation data from GARD®skin for Medical Devices: In vitro skin sensitization testing of Medical Device Extracts for implementation in ISO 10993-10.\nRegulatory Developments in ISO 10993-10: Inclusion of in vitro methods.\nCase study: Integrating in vitro data into CE-marking submissions.\n\n\n“Biocompatibility evaluation of substance-based medical devices”\n Friday\, 7th Nov | 11:40 – 12:10 CET\n👤 Speaker: Dr Carla Landolfi\nKey takeaways:\n\nOverview of biocompatibility evaluation for substance-based medical devices under ISO 10993 and MDR.\nTesting strategies: in vitro\, in vivo\, and non-testing approaches.\nRegulatory challenges and best practices for ensuring patient safety.
URL:https://senzagen.com/event/3rd-annual-medical-device-biocompatibility-conference/
LOCATION:Berlin\, Germany
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2025/08/MD-Biocompatibility-conference-in-Berlin-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260322
DTEND;VALUE=DATE:20260326
DTSTAMP:20260312T111337Z
CREATED:20260122T141811Z
LAST-MODIFIED:20260312T111337Z
UID:36486-1774137600-1774483199@senzagen.com
SUMMARY:2026 SOT Annual Meeting & ToxExpo
DESCRIPTION:Booth #1934\nSan Diego\, CA\, USA\nJoin our scientific sessions and poster presentations at this year’s SOT\, featuring the latest GARD® data and case studies generated in collaboration with industry leaders. \nMeet us at booth #1934 and discuss your specific testing needs with our scientific team – We help you design testing strategies tailored to your substances and regulatory goals: from “2 out of 3” defined approaches according to OECD 497\, to exploratory studies supporting product development. \n \nExhibitor-Hosted Session\nAdvancing NAMs for Skin and Respiratory Sensitization: UVCBs\, Natural Extracts and Medical Devices \nNew GARD® advances in respiratory sensitization\,  ISO 10993-10 compliance for medical devices\, quantitative potency assessment\, and difficult-to-test samples \nRoom 23A | Tue\, 24 March | 10:45 am-11:45 am\n \n1. Introduction to GARD® technology for skin and respiratory sensitization testing \n🎤Andy Forreryd\, PhD |  Scientific Liaison\, SenzaGen  \n2. Evaluating sensitization potential of medical devices in vitro using GARD®skin assay: a practical in vitro sensitization case study in medical device development \n🎤Yizhong Liu\, PhD\, DABT | Senior Scientist and Toxicologist\, Johnson & Johnson MedTech  \n3. GARD®air for the prediction of respiratory sensitization for substances of regulatory concern \n🎤Emily Reinke\, PhD\, DABT | Principal Toxicologist\, GDIT (contractor supporting NICEATM)  \n4. Respiratory sensitization hazard identification: navigating assay exploration for biocatalytic enzymes \n🎤Joshua Vaughan\, PhD\, DABT | Principal Scientist\, Merck  \nSpeaking in Symposium Sessions\nIn Vitro Testing for Skin Sensitization of Mixtures: Where Science Stands Today \nRoom 7B | Wed\, 25 March | 8:00 am-10:45 am \nChairs: The Honest Company\, Edgewell Personal Care | SenzaGen: Dr Tim Lindberg | SenzaGen: Dr Tim Lindberg \nHuman Health Risk Assessments of Biopesticides: Evaluating Safety for Agricultural Use \nBallroom 6F | Wed\, 25 March | 1:30 PM-4:15 PM \nChairs: Bayer Crop Science\, Corteva Agriscience | SenzaGen: Dr Andy Forreryd \nPosters\n🎫 K764 | #5200 | Case study: Fragrance formulations – Jointly with Coty \nImproving the safety profiles of fragrance formulations: modulating the skin sensitization potential to reduce or eliminate the risk of allergic skin reactions \n🎫 K762 | #5198 | Case study: 2o3 DA applied to UVCBs – Jointly with ExxonMobil \nApplying the “2 out of 3” Defined Approach (OECD 497) to assess skin sensitization potential of UVCBs using the GARD®skin and EpiSensA assays \n🎫 K759 | #5195 | Case study: NESIL prediction for OTC drugs – Jointly with Haleon  \nPredicting NESIL using New Approach Methodologies: a case study on quantitative skin sensitization assessment of topical over-the-counter pharmaceutical candidates \n🎫B175 | #3072 | Medical Device ISO 10993-10 \nIn vitro sensitization assessment of medical device extracts: Prevalidation results of GARD®skin Medical Device for potential inclusion in ISO 10993-10 \n🎫G546 | #3403 | New alternative gene expression platform for GARD® \nRNA-seq can be used for gene expression quantification in the GARD®skin method for assessment of skin sensitizers
URL:https://senzagen.com/event/2026sot/
LOCATION:San Diego\, CA\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2026/01/2026-SOT-eventpage-banner-2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20260610T080000
DTEND;TZID=Europe/Stockholm:20260612T170000
DTSTAMP:20260522T121714Z
CREATED:20260424T124413Z
LAST-MODIFIED:20260522T121714Z
UID:36953-1781078400-1781283600@senzagen.com
SUMMARY:2026 AFI Symposium
DESCRIPTION:Meet SenzaGen group companies VitroScreen and ToxHub at the 65th AFI Symposium\, June 10-12\, at the Palacongressi in Rimini. \nMeet SenzaGen Group at booth No. 5\nAt the event\, VitroScreen and ToxHub will showcase how our combined scientific capabilities support pharma and medical device development through non-animal safety and efficacy testing approaches\, and regulatory toxicology and pharmacology consultancy. \nPosters: Film-forming effect\, biorevitalizing activity of hyaluronic acid–based devices\nVitroScreen will present new preclinical data using advanced human-relevant models for non-animal efficacy testing of substance-based medical devices\, including the spheroid-based platform VitroScreenORA: \n🎫 Assessment of the film-forming effect of substance-based medical devices on reconstructed human epithelia in vitro \n🎫 Preclinical evaluation of the biorevitalizing activity of hyaluronic acid–based medical devices using an innovative aged human dermal spheroid platform \nToxHub contributes with expertise in regulatory toxicology and risk assessment\, with a special focus on impurity qualification: \n🎫 The qualification for non-mutagenic impurities for high potent APIs
URL:https://senzagen.com/event/2026-afi-symposium/
LOCATION:Rimini\, Italy
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2026/04/AFI-banner.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260629
DTEND;VALUE=DATE:20260703
DTSTAMP:20260630T092524Z
CREATED:20260123T090400Z
LAST-MODIFIED:20260630T092524Z
UID:36525-1782691200-1783036799@senzagen.com
SUMMARY:ESTIV 2026
DESCRIPTION:Maastricht\, the Netherlands\n“Ensuring Safety\, Advancing Science: Bridging to the Future with NAMs” \nPosters\nTuesday\, 30 June \nP23: #272 – “Adapting RNA-seq as an alternative acquisition platform for gene expression quantification in the GARDskin assay” \np71: #269 – “In vitro sensitization assessment of medical device extracts: Prevalidation results of GARDskin Medical Device for potential inclusion in ISO 10993-10”
URL:https://senzagen.com/event/estiv-2026/
LOCATION:Maastricht
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2026/01/2026-ESTIV-eventpage-banner-3.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260913
DTEND;VALUE=DATE:20260917
DTSTAMP:20260827T083829Z
CREATED:20260123T082112Z
LAST-MODIFIED:20260827T083829Z
UID:36512-1789257600-1789603199@senzagen.com
SUMMARY:Eurotox 2026
DESCRIPTION:Come meet us at Booth #58 and join our scientific session and poster presentations\, showcasing the latest GARD® data and case studies generated in collaboration with industry leaders. \n \nSenzaGen-hosted session\nHall M | Tuesday\, 15 September | 12:15 – 13:15\nAdvancing NAMs for skin and respiratory sensitization testing: Industry case studies on Essential Oils\, Natural Extracts\, and Difficult-to-test samples\n \nFeaturing guest speakers from ExxonMobil\, dōTERRA\, and the Research Institute for Fragrance Materials (RIFM)\, this session will highlight how GARD® data support Quantitative Risk Assessment and regulatory testing under OECD DA 497. \n  \nAgenda\n1. Introduction to the GARD® technology for skin and respiratory sensitization testing \nAndy Forreryd\, PhD |  Scientific Liaison\, SenzaGen \n2. Application of the “2 out of 3” Defined Approach (OECD 497) to assess skin sensitization potential of Difficult-to-test substances \nMegan Solan\, PhD | Toxicologist\, ExxonMobil Biomedical Sciences \n3. A comparative analysis of test methods for predicting dermal sensitization potency in Essential Oils \nJoe Dawson | Product Safety Manager\, dōTERRA \n4. Case study of GARD®skin Dose-Response on Natural Extracts and Quantitative Risk Assessment \nIsabelle Lee\, PhD | Manager of Human Health Science and Strategy\, RIFM \nPoster presentations\nSpotlight on Natural Complex Substances and In silico methods for Enviromental Risk Assessment\n P21-22 #1612 | Joint poster presented by ICCS \nRoom 0.11-0.12 | Tue\, 15 September | 09:30 \nAdaptation of the Next‑Generation Risk Assessment Framework for Skin Sensitization for the use of Natural Complex Substances  \n P18-74 #1159 | Poster presented by ToxHub \nRoom 0.11-0.12 | Mon\, 14 September | 09:30 \nReliability of QSAR-Based LogKow predictions in pharmaceutical Environmental Risk Assessment \nMore at our booth\nRegulatory expertise now complemented by in silico toxicology services\nMeet ToxHub\, our consultancy unit specializing in toxicological risk assessment and regulatory strategy consulting\, with expertise across medical devices\, pharmaceuticals\, cosmetics and chemicals. \nToxHub has recently lauched a new in silico toxicology service area\, providing QSAR-based hazard profiling to support both human health and environmental endpoints. \nDiscover how ToxHub can support your needs
URL:https://senzagen.com/event/eurotox-2026/
LOCATION:Vienna\, Austria
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2026/01/Lime-Evite_2026-Eurotox-Lime-banner_v1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261013
DTEND;VALUE=DATE:20261015
DTSTAMP:20261009T083301Z
CREATED:20260916T104449Z
LAST-MODIFIED:20261009T083301Z
UID:37458-1791849600-1792022399@senzagen.com
SUMMARY:Biocompatibility Insights 2026
DESCRIPTION:Biocompatibility Insights 2026\n Copenhagen\, Denmark\nDr. Andy Forreryd has been invited to speak at Biocompatibility Insights 2026. His presentation will focus on the growing adoption of non-animal methods in medical device testing\, highlighting regulatory updates and industry applications. \n  \n \n 
URL:https://senzagen.com/event/biocompatibility-insights-2026/
LOCATION:Copenhagen\, Denmark
CATEGORIES:Conference
ATTACH;FMTTYPE=image/jpeg:https://senzagen.com/wp-content/uploads/2026/09/2026-Biocompatibility-insights-event-page-banner.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20261115
DTEND;VALUE=DATE:20261119
DTSTAMP:20261110T080858Z
CREATED:20260911T135953Z
LAST-MODIFIED:20261110T080858Z
UID:37420-1794700800-1795046399@senzagen.com
SUMMARY:ACT 2026
DESCRIPTION:American College of Toxicology (ACT) 47th Annual Meeting\n San Antonio\, USA\nAdvancing NAMs for Skin and Respiratory Sensitization Testing\nGARD®air for occupational health-related chemicals | Microorganisms | Proteins \nJoin us to discuss the latest developments in GARD® technology and explore how genomics- and machine learning-based approaches are supporting human-relevant sensitization assessment for product development and regulatory decision-making. \n \nPoster: Essential oils and quantitative potency assessment\nMonday\, 16 November\, 5:00 pm -6:30 pm \nDr Tim Lindberg | P204 | #2444913 – “Assessing skin sensitization potency and thresholds in Essential Oils: A comparative study using human data\, LLNA\, and GARD®skin Dose-Response” \n  \nNew: Immunotoxicology and biologics\nMonoclonal Antibodies | T-Cell Engagers | Bispecific Therapies \nWe are pleased to welcome Alcyomics to the SenzaGen Group\, expanding our capabilities in non-animal immunotoxicology and drug development\, with particular expertise in advanced biologics. \nRead more about Alcyomics
URL:https://senzagen.com/event/act2026/
LOCATION:San Antonio\, TX\, United States
CATEGORIES:Conference
ATTACH;FMTTYPE=image/png:https://senzagen.com/wp-content/uploads/2026/09/ACT-am26-banner-event-page.png
END:VEVENT
END:VCALENDAR